Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors.

Barth RF, Wu G, Meisen WH, Nakkula RJ, Yang W, Huo T, Kellough DA, Kaumaya P, Turro C, Agius LM, Kaur B.

Onco Targets Ther. 2016 May 10;9:2769-81. doi: 10.2147/OTT.S99242. eCollection 2016.

2.

Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).

Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT.

Vaccines (Basel). 2015 Jul 6;3(3):519-43. doi: 10.3390/vaccines3030519.

3.

HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.

Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT.

Oncoimmunology. 2014 Dec 21;3(11):e956012. eCollection 2014 Nov.

4.

IGF-1R peptide vaccines/mimics inhibit the growth of BxPC3 and JIMT-1 cancer cells and exhibit synergistic antitumor effects with HER-1 and HER-2 peptides.

Foy KC, Miller MJ, Overholser J, Donnelly SM, Nahta R, Kaumaya PT.

Oncoimmunology. 2014 Dec 21;3(11):e956005. eCollection 2014 Nov.

6.

Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.

Sanabria-Figueroa E, Donnelly SM, Foy KC, Buss MC, Castellino RC, Paplomata E, Taliaferro-Smith L, Kaumaya PT, Nahta R.

Mol Pharmacol. 2015 Feb;87(2):150-61. doi: 10.1124/mol.114.095380. Epub 2014 Nov 12.

7.

Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics.

Kaumaya PT.

Immunotherapy. 2013 Nov;5(11):1159-63. doi: 10.2217/imt.13.128. Review. No abstract available.

PMID:
24188668
8.

Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.

Foy KC, Wygle RM, Miller MJ, Overholser JP, Bekaii-Saab T, Kaumaya PT.

J Immunol. 2013 Jul 1;191(1):217-27. doi: 10.4049/jimmunol.1300231. Epub 2013 May 22.

9.
11.
12.
13.

Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Kaumaya PT, Foy KC.

Future Oncol. 2012 Aug;8(8):961-87. doi: 10.2217/fon.12.95. Review.

14.

Could precision-engineered peptide epitopes/vaccines be the key to a cancer cure?

Kaumaya PT.

Future Oncol. 2011 Jul;7(7):807-10. doi: 10.2217/fon.11.60. No abstract available.

15.

Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo.

Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT.

J Biol Chem. 2011 Apr 15;286(15):13626-37. doi: 10.1074/jbc.M110.216820. Epub 2011 Feb 16.

16.

Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.

Vicari D, Foy KC, Liotta EM, Kaumaya PT.

J Biol Chem. 2011 Apr 15;286(15):13612-25. doi: 10.1074/jbc.M110.216812. Epub 2011 Feb 14.

17.

Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy.

Peterson JM, Kline W, Canan BD, Ricca DJ, Kaspar B, Delfín DA, DiRienzo K, Clemens PR, Robbins PD, Baldwin AS, Flood P, Kaumaya P, Freitas M, Kornegay JN, Mendell JR, Rafael-Fortney JA, Guttridge DC, Janssen PM.

Mol Med. 2011 May-Jun;17(5-6):508-15. doi: 10.2119/molmed.2010.00263. Epub 2011 Jan 20.

18.

Immunization with synthetic VEGF peptides in ovarian cancer.

Wang B, Kaumaya PT, Cohn DE.

Gynecol Oncol. 2010 Dec;119(3):564-70. doi: 10.1016/j.ygyno.2010.07.037. Epub 2010 Sep 6.

19.

Design and use of peptide-based antibodies decreasing superoxide production by mitochondrial complex I and complex II.

Kang PT, Yun J, Kaumaya PP, Chen YR.

Biopolymers. 2011;96(2):207-21. doi: 10.1002/bip.21457.

20.

Peptide-based antibodies against glutathione-binding domains suppress superoxide production mediated by mitochondrial complex I.

Chen J, Chen CL, Rawale S, Chen CA, Zweier JL, Kaumaya PT, Chen YR.

J Biol Chem. 2010 Jan 29;285(5):3168-80. doi: 10.1074/jbc.M109.056846. Epub 2009 Nov 23.

Supplemental Content

Loading ...
Support Center